Status:
COMPLETED
A Study of VAH631 in Patients With Essential Hypertension (Factorial Study)
Lead Sponsor:
Novartis
Conditions:
Hypertension
Eligibility:
All Genders
20-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to compare the effect of the fixed combination of valsartan+hydrochlorothiazide (HCTZ) on blood pressure reduction with valsartan and HCTZ alone and whether the combinatio...
Eligibility Criteria
Inclusion
- Essential hypertension measured by mercury sphygmomanometer
- Outpatients
Exclusion
- Secondary hypertension or suspected of having secondary hypertension.
- A history of malignant hypertension
- Severe hypertension
- Significant heart, renal, hepatic diseases or significant cerebrovascular disorder
- Gout Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
March 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2006
Estimated Enrollment :
582 Patients enrolled
Trial Details
Trial ID
NCT00311740
Start Date
March 1 2006
End Date
September 1 2006
Last Update
February 23 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Pharmaceuticals
Tokyo, Japan